A high ratio of serum AST (GOT)/ALT before NAB-paclitaxel and GEM chemotherapy in advanced PC patients is associated with poor prognosis and can be used as a new indicator for risk assessment of individualized treatment of PC (Riedl et al., 2020). The gene discussed is GPT; the disease is pachyonychia congenita.